Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of DZD2269 in Healthy Participants
NCT04932005Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in solid tumor comparing DZD2269 with Placebo (2 arms). Primary endpoints: Number and percentage of participants with adverse event (AE), Number and percentage of participants with serious adverse event (SAE) and 3 more. Started Jun 2021; status: completed.
02
Drugs
DZD2269
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04932005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04932005.